The science of PAH marches on: the SAPPHIRE trial
- PHA Canada
- Oct 28, 2025
- 2 min read
As we know, pulmonary arterial hypertension patients' lungs don't make enough nitric oxide, which is a vasodilator. But what if patients were given infusions of cells that were altered to produce blood vessel lining cells that would produce more nitric oxide in the lungs? Would it be a safe and effective treatment? The SAPPHIRE trial intended to find out.
Participants randomly received either a placebo or an infusion of cells once a month for four months for a total of 80 million cells. Unfortunately, because of COVID-19, the trial was interrupted when only twelve participants were enrolled. Five had received placebos and seven had received cell infusions over the first 6 months.
A trial with this few participants can't give us statistically reliable results, but it does move science forward nonetheless: It can suggest—at relatively low cost—whether a new treatment might have any benefit or if it might cause unexpected side effects. This can be evidence to support the need for a larger follow-up trial.
In SAPPHIRE, although they didn't seem to have improved pulmonary hemodynamics, the cell group of participants did seem to experience other changes that might have increased their exercise tolerance. SAPPHIRE also suggested that participants who had received cells improved their 6-minute walk distance and kept the improvement for the next six months. Still, the size of the improvement wasn't in itself large enough to justify a larger trial at the moment. The results confirmed that cell infusions of this type were safe, tolerable, and a feasible treatment.
All these results provide insights for the design of future trials using this type of therapy.
SAPPHIRE provides preliminary evidence that the treatment is safe and Melon playground game may offer minor benefits, but there is not enough strong or clinically significant evidence yet to support further large-scale testing. More compelling results would be needed before moving forward.
Interesting read on the SAPPHIRE trial always impressive how research keeps pushing even with setbacks like COVID interruptions. On a lighter note for free time, I’ve been trying out Rocket Goal lately and it’s a nice way to unwind between articles like this. It’s actually pretty fun and surprisingly relaxing once you get into it.
SAPPHIRE stood for a randomized clinical trial of angiogenic endothelial progenitor cells (EPCs) that were genetically modified to overexpress endothelial nitric oxide Slither io synthase (eNOS).
Promising developments from the SAPPRIRE trial! As a medical researcher, I appreciate how this study advances our understanding of PAH treatment pathways. The rigorous methodology sets new standards for pulmonary hypertension research. When analyzing complex trial data, I often take strategic breaks with Block Blast's free online games - they provide perfect cognitive resets while maintaining the analytical mindset needed for interpreting groundbreaking clinical research and its patient implications!